Builds on successful U.S. biosimilar partnership of 2 oncology
products (RELEUKO® & FYLNETRA®)
ADL018 is Kashiv’s lead pipeline biosimilar program, currently
in Phase III
Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today
announced that it has entered into an exclusive licensing agreement
for ADL018, a proposed biosimilar to omalizumab referencing
XOLAIR®, with Amneal Pharmaceuticals, Inc. (“Amneal”) for the
United States.
Omalizumab, which targets free IgE, is a humanized monoclonal
antibody. It is an injectable prescription drug used to treat a
number of chronic conditions such as severe persistent allergic
asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food
allergies, and chronic spontaneous urticaria, and is typically
administered in a hospital or clinic setting. The biosimilar was
developed by Kashiv BioSciences, LLC and is currently in a Phase
III clinical trial, which began in the third quarter of 2023.
“We are pleased to partner with Amneal, a leader in
commercialization of biologics in the US, on our most advanced
pipeline product, ADL018, a proposed biosimilar to XOLAIR®. We are
building on our highly productive partnership with the commercial
success of RELEUKO® & FYLNETRA®. Kashiv is one of a few
companies based in the United States to manufacture and receive
marketing authorization of multiple biosimilars. By relentlessly
focusing on quality and cost-effective development, Kashiv
continues to build upon its strong track record of developing and
manufacturing high-quality, affordable biosimilars to improve
patients’ lives worldwide,” said Dr. Sandeep Gupta, Chief Executive
Officer of Kashiv.
“We are excited to further grow our biosimilar portfolio with
the addition of omalizumab and expand into a new therapeutic area
beyond oncology. We are building on the strong success of our first
commercial biosimilars. Amneal is committed to providing affordable
biologic medicines which will increase access and choice to
patients and providers, and drive cost savings to the U.S.
healthcare system,” said Sean McGowan, Vice President, Biosimilars
and Branded Oncology.
According to IQVIA®, U.S. annual sales for XOLAIR® for the 12
months ended April 2024 were approximately $3.2 billion. XOLAIR® is
a registered trademark of Novartis AG.
The financial terms of the transaction were not disclosed, and
any incremental expenses associated with these products are
contemplated within Amneal’s guidance.
About Kashiv Biosciences, LLC
Kashiv Biosciences, LLC is a fully integrated biopharmaceutical
company with global R&D, clinical, regulatory, and
manufacturing capabilities for developing biosimilars and other
complex products. The Company has a robust pipeline of 7+
biosimilars, and multiple 505(b)(2) and complex peptide generic
products in development. Kashiv is headquartered in Piscataway, NJ
with FDA-approved GMP manufacturing facilities in Chicago, IL and
state-of-the-art R&D infrastructure in Ahmedabad, India. For
more information, visit www.kashivbiosciences.com.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in
Bridgewater, NJ, is a global pharmaceuticals company. We make
healthy possible through the development, manufacturing, and
distribution of a diverse portfolio of over 280 pharmaceutical
products, primarily within the United States. In its Generics
segment, Amneal is expanding across a broad range of complex
product categories and therapeutic areas, including injectables and
biosimilars. In its Specialty segment, Amneal has a growing
portfolio of branded pharmaceuticals focused primarily on central
nervous system and endocrine disorders, with a pipeline focused on
unmet needs. Through its AvKARE segment, Amneal is a distributor of
pharmaceuticals and other products for the U.S. federal government,
retail, and institutional markets. For more information, please
visit www.amneal.com.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are
not historical facts, may be forward-looking statements (as defined
in the U.S. Private Securities Litigation Reform Act of 1995). Such
forward-looking statements include statements regarding
management’s intentions, plans, beliefs, expectations, financial
results, or forecasts for the future, including among other things:
discussions of future operations; expected or estimated operating
results and financial performance; and statements regarding our
positioning, including our ability to drive sustainable long-term
growth, and other non-historical statements. Words such as “plans,”
“expects,” “will,” “anticipates,” “estimates,” and similar words,
or the negatives thereof, are intended to identify estimates and
forward-looking statements.
The reader is cautioned not to rely on these forward-looking
statements. These forward-looking statements are based on current
expectations of future events, including with respect to future
market conditions, company performance and financial results,
operational investments, business prospects, new strategies and
growth initiatives, the competitive environment, and other events.
If the underlying assumptions prove inaccurate or known or unknown
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections of Amneal.
Such risks and uncertainties include, but are not limited to:
our ability to successfully develop, license, acquire and
commercialize new products on a timely basis; the competition we
face in the pharmaceutical industry from brand and generic drug
product companies, and the impact of that competition on our
ability to set prices; our ability to obtain exclusive marketing
rights for our products; our revenues are derived from the sales of
a limited number of products, a substantial portion of which are
through a limited number of customers; the impact of a prolonged
business interruption within our supply chain; the continuing trend
of consolidation of certain customer groups; our dependence on
third-party suppliers and distributors for raw materials for our
products and certain finished goods; legal, regulatory and
legislative efforts by our brand competitors to deter competition
from our generic alternatives; our dependence on information
technology systems and infrastructure and the potential for
cybersecurity incidents; our ability to attract, hire and retain
highly skilled personnel; risks related to federal regulation of
arrangements between manufacturers of branded and generic products;
our reliance on certain licenses to proprietary technologies from
time to time; the significant amount of resources we expend on
research and development; the risk of claims brought against us by
third parties; risks related to changes in the regulatory
environment, including U.S. federal and state laws related to
healthcare fraud abuse and health information privacy and security
and changes in such laws; changes to Food and Drug Administration
product approval requirements; the impact of healthcare reform and
changes in coverage and reimbursement levels by governmental
authorities and other third-party payers; our dependence on
third-party agreements for a portion of our product offerings; our
substantial amount of indebtedness and our ability to generate
sufficient cash to service our indebtedness in the future, and the
impact of interest rate fluctuations on such indebtedness; our
potential expansion into additional international markets
subjecting us to increased regulatory, economic, social and
political uncertainties; our ability to identify, make and
integrate acquisitions or investments in complementary businesses
and products on advantageous terms; the impact of global economic,
political or other catastrophic events; our obligations under a tax
receivable agreement may be significant; and the high concentration
of ownership of our Class A common stock and the fact that we are
controlled by the Amneal Group. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in Amneal’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in Amneal’s most recent Annual Report
on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K.
Investors are cautioned not to place undue reliance on any such
forward-looking statements, which speak only as of the date they
are made. Forward-looking statements included herein speak only as
of the date hereof and we undertake no obligation to revise or
update such statements to reflect the occurrence of events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702506268/en/
Dr. Paras Vasanani Head of BD&L, Portfolio Strategy
paras.vasanani@kashivbio.com Anthony DiMeo VP, Investor Relations
& Media anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
過去 株価チャート
から 10 2024 まで 11 2024
Amneal Pharmaceuticals (NYSE:AMRX)
過去 株価チャート
から 11 2023 まで 11 2024
